Intra-bone marrow transplantation confers superior multilineage engraftment of murine aorta-gonad mesonephros cells over intravenous transplantation
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sanjuan-Pla, Alejandraca
- dc.contributor.author Romero-Moya, Damiàca
- dc.contributor.author Prieto, Cristinaca
- dc.contributor.author Bueno, Claraca
- dc.contributor.author Bigas Salvans, Annaca
- dc.contributor.author Menéndez, Pabloca
- dc.date.accessioned 2016-03-02T11:50:10Z
- dc.date.issued 2016
- dc.description.abstract Hematopoietic stem cell (HSC) engraftment has been achieved using single-cell transplantation of prospectively highly purified adult HSC populations. However, bulk transplants are still performed when assessing the HSC potential of early embryonic hematopoietic tissues such as the aorta-gonad mesonephros (AGM) due to very low HSC activity content early in development. Intra-bone marrow transplantation (IBMT) has emerged as a superior administration route over intravenous (IV) transplantation for assessing the reconstituting ability of human HSCs in the xenotransplant setting since it bypasses the requirement for homing to the BM. In this study, we compared the ability of IBMT and IV administration of embryonic day 11.5 AGM-derived cells to reconstitute the hematopoietic system of myeloablated recipients. IBMT resulted in higher levels of AGM HSC long-term multilineage engraftment in the peripheral blood, BM, spleen, and thymus of primary and secondary recipients, and in limiting dilution experiments. The administration route did not skew the multilineage contribution pattern, but IBMT conferred higher Lineage(-)Sca-1(+)c-kit(+) long-term engraftment, in line with the superior IBMT reconstitution. Therefore, IBMT represents a superior administration route to detect HSC activity from developmentally early sources with limited HSC activity content, such as the AGM.ca
- dc.description.sponsorship This work was supportedbythe European Research Council CoG to P.M., the Spanish Ministry of Economy and Competitiveness (ISCIII/FEDER PI14/01119 to C.B and SAF2013-43065R to P.M), the Spanish Association Against Cancer to P.M. and C.B., the Fundación Inocente Inocente to PM, a Marie Curie Career Integration Grant to A.S-P (FP7-PEOPLE-2013-CIG-631171), and the Josep Carreras Dutch Leukemia Fund to P.M and ASP. C.B. is supported by a Miguel Servet II contract (CPII13/00011). C.P. is supported by PFIS scholarship (FI12/00468). P.M. also acknowledges the financial support from The Obra Social La Caixa-Fundació Josep Carreras and The Generalitat de Catalunya (SGR330).
- dc.format.mimetype application/pdfca
- dc.identifier.citation Sanjuan-Pla A, Romero-Moya D, Prieto C, Bueno C, Bigas A, Menendez P. Intra-bone marrow transplantation confers superior multilineage engraftment of murine aorta-gonad mesonephros cells over intravenous transplantation. Stem Cells Dev. 2016 Feb 1;25(3):259-65. doi: 10.1089/scd.2015.0309.ca
- dc.identifier.doi http://dx.doi.org/10.1089/scd.2015.0309
- dc.identifier.issn 1547-3287
- dc.identifier.uri http://hdl.handle.net/10230/25962
- dc.language.iso engca
- dc.publisher Mary Ann Liebertca
- dc.relation.ispartof Stem Cells and Development. 2016 Feb 1;25(3):259-65
- dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/631171
- dc.rights Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/scd.2015.0309ca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.other Hematopoiesica
- dc.subject.other Sang -- Malaltiesca
- dc.title Intra-bone marrow transplantation confers superior multilineage engraftment of murine aorta-gonad mesonephros cells over intravenous transplantationca
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/acceptedVersionca